First experience on crizotinib therapy in non small cell lung cancer patient with EML-4 ALK translocation in Czech republic

Abstract

Translocation of ALK gene is knošn as one of driving oncogenic mechanism in some of NSCLC patients. Crizotinib is a new effective targeted drug which should be geven to such patients.

Our 56 years old patient having stage IV adenocarcinoma, never-smoker is succesfuly treated more than one year without serious adverse events.

Keywords

• translocation of ALK gene
• crizotinib
• targeted therapy
• lung cancer in never smokers